Comparing two biologic drugs for ankylosing spondylitis
Part of Bones, joints & muscles clinical trials.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with axial spondyloarthritis (a type of inflammatory arthritis in the spine) according to standard medical criteria.
- Your symptoms must have lasted more than 6 months.
- You have already tried standard treatments (like NSAIDs) and they didn't work, so you are now on a biologic drug (either an IL-17 inhibitor or an anti-TNF drug).
- You are between 16 and 60 years old.
- You are able to answer questions and give written permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
This trial tests whether stem cells from donated bone marrow can reduce inflammation and pain in ankylosing spondylitis, a condition that causes the spine to become stiff and inflamed. Researchers will monitor how safe and effective this treatment is for eligible patients.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who are otherwise healthy. It may test a treatment to see if it helps control symptoms, whether your disease is active or stable.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.